United Therapeutics Corporation (UTHR) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong near‑term setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETON‑2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into mid‑March. Combination of active repurchases, de‑risked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High margins • Strong liquidity • Premium valuation UTHR is a cash-rich, highly profitable company with exceptionally strong margins and conservative leverage, but it trades at a material premium and shows notable cash deployment in financing.
Price Behavior
Key Price Behavior Insights: • Recent breakout • Elevated volatility • Pullback risk Support Level: $473–$485 Resistance Level: $535 UTHR is in a short-term uptrend over the last month, breaking the multi-test $500–$515 zone on a concentrated March 6–9 surge but carrying elevated intraperiod volatility that raises pullback risk.
Sentiment & News
Key News Insights: • Record revenue • $3.5B buybacks • Tyvaso DPI growth United Therapeutics beat Q4 estimates, drove record 2025 revenue, raised guidance and initiated a $3.5B capital-return program while product and clinical milestones (including Tyvaso DPI growth and a new inhaler) suggest continued upside amid some mixed underlying metrics and portfolio churn.
AI Summary
United Therapeutics should be reclassified from a defensive, buyback-driven cash cow to a pipeline-led growth stock whose premium valuation now depends on timely ralinepag approval and rapid Tyvaso DPI commercialization—track ralinepag regulatory timing, DPI manufacturing/payer execution, and insider selling as the decisive catalysts. Action: accumulate only if you assign high probability to those execution outcomes; otherwise trim to neutral/avoid given elevated multiples and downside from misses.
Description
United Therapeutics is a biopharmaceutical company that develops and markets therapies for chronic and life‑threatening conditions, with a primary emphasis on pulmonary hypertension and select oncology indications. Its commercial portfolio includes injectable, inhaled and oral prostacyclin‑based treatments for pulmonary arterial hypertension and an antibody therapy for high‑risk neuroblastoma, while its development pipeline comprises inhalation devices, a wearable drug pump, oral agents, gene therapy and ongoing clinical programs in related pulmonary disorders. The company maintains strategic collaborations for device and drug development and is based in Silver Spring, Maryland, where it was incorporated in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 13 | Mar 20 | UTHR | United Therapeutics Corporation | Strong near‑term setup: large capital return (up to $2B buyback and $1.5B ASR started 2026-03-09), two positive Phase 3 readouts in March (ralinepag ADVANCE OUTCOMES 2026-03-02 and nebulized Tyvaso TETON‑2 NEJM IPF data 2026-03-11), record FY2025 revenue and >40% net margin, plus ~+13.5% price move into mid‑March. Combination of active repurchases, de‑risked pipeline and technical breakout supports continued upside over the next few days, albeit with biotech volatility. | Active | +0.0% |